Effect of capecitabine on breast cancer failing in treatment with different receptor expression
10.3760/cma.j.jssn.1673-4904.2016.06.023
- VernacularTitle:卡培他滨单药维持治疗不同受体表达治疗失败的乳腺癌的临床研究
- Author:
Yonghong WAN
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoplasm recurrence,local;
Capecitabine
- From:
Chinese Journal of Postgraduates of Medicine
2016;39(6):558-560
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of capecitabine alone against breast cancer failing in treatment with different receptor expression. Methods Ninety-six cases of breast cancer patients failing in treatment with different receptor expression were collected. They were treated with capecitabine alone, 1 000-1 250 mg/m2, D1-14, 21 d for 1 cycle. All the treatment was repeated 3 cycles at least. According to age, menopausal status, Eastern Cooperative Oncology Group (ECOG) scores, estrogen and progesterone receptor status, human epidermal growth factor receptor-2 expression, number of chemotherapy cycle, the patients were divided into difference groups. χ2 test was used to do single factor analysis and the independent factor affecting the progression free survival time (PFS) was analyzed by Cox regression model. Results The rate of objective effect in 96 breast cancer patients was 51.0%(49/96). PFS was 2-46 months, and median time was 7.0 months. In hematologic toxicity:Ⅰdegree was in 4 cases,Ⅱdegree in 3 cases, andⅢdegree in 5 cases. In digestive tract toxicity:Ⅰdegree was in 5 cases, andⅡdegree in 4 cases. In hand foot syndrome: I degree was in 3 cases, Ⅱ degree was in 1 case, and Ⅲ degree in 1 cases. Cox regression model showed that the number of chemotherapy cycle was the independent factor affecting the PFS (OR = 6.45, 95% CI 3.04- 13.71, P<0.01). Conclusions The treatment of breast cancer with capecitabine alone has good curative effect, and the number of chemotherapy cycles number is the independent influencing factor of RFS.
